Fondazione Ricerca e Innovazione Cardiovascolare Completes Enrollment in TRANSFORM II RCT, A landmark study comparing MagicTouch SCB vs DES in Native Coronary Vessels
CLEVELAND, June 13, 2025 /CNW/ -- Primary Investigator, Bernardo Cortese MD, proudly announces the successful completion of patient enrollment in the TRANSFORM II randomized controlled trial (RCT). This pivotal study aims to evaluate the safety and efficacy of the MagicTouch Sirolimus-Coated Balloon (SCB) compared to an everolimus-eluting stent (EES) in treating de-novo coronary vessels.
TRANSFORM II (Sirolimus-Coated Balloon Versus Drug-Eluting Stent in Native Coronary Vessels) is an investigator-driven trial sponsored by Fondazione Ricerca e Innovazione Cardiovascolare in Milano, Italy, and has now achieved its target enrollment of >1,820 patients. The final patient was enrolled on 6 th June 2025, marking a major milestone for the trial. Led by Study Chairman Prof. Bernardo Cortese (University Hospitals Harrington Heart & Vascular Institute, Cleveland, USA) and a distinguished steering committee, TRANSFORM II is one of the largest global randomized controlled trials evaluating drug-coated balloon and has enrolled patients from 52 centers across Europe, Asia and South America. Key features of the TRANSFORM II trial include:
Comparative Arms: MagicTouch SCB vs. Everolimus-Eluting Stent (EES)
Patient Population: 1,832 patients with de-novo lesions in coronary arteries (vessel diameter >2.0 mm to ≤3.5 mm; lesion length ≤50 mm)
Primary Endpoint: Target Lesion Failure at 12 months, non-inferiority design
Follow-Up: Patients will be monitored for up to 60 months (5 years)
Sub-Study: Optical Coherence Tomography (OCT) imaging in 70 patients at 9 months to assess angiographic outcomes
Prof. Bernardo Cortese, Study Chairman of TRANSFORM II, commented: "After 3 and a half years we were able to complete the enrollment in TRANSFORM II trial, a study that involved 52 centers across 3 continents, and this is amazing. The effort put by our Team in Fondazione RIC and each Investigator of the study led to a quite fast enrollment in such a big, ambitious study. Our goal is to advance the adoption of DCB in the coronary space, testing this sirolimus DCB with the most studied and used DES, in a daily patient population. Along with the guidance of the recently published DCB ARC guidelines, we are paving the route for the modern angioplasty era!".
Coronary vessels of this size (which account for roughly 80% of patients undergoing percutaneous coronary interventions) present unique treatment challenges. Currently, interventional cardiologists must often choose a permanent implant namely a drug-eluting stent — effectively "caging" a small vessel — which may compromise long-term outcomes. The head-to-head comparison of MagicTouch SCB against a current standard of care (the EES family of drug-eluting stents) in TRANSFORM II is poised to provide critical evidence for an alternative approach. This trial has the potential to reshape treatment practices by establishing drug-coated balloons as the next viable option for patients with coronary artery disease.
Drug-coated balloon technology has long been viewed as a promising solution for small, de-novo coronary lesions, and sirolimus is a viable alternative to the first generation of DCB eluting paclitaxel. Data from this large-scale RCT are expected to support a paradigm shift towards broader use of drug-coated balloons. Implanting a drug-eluting stent in a tiny artery is far from ideal for both patients and physicians, so a rigorous study validating the use of SCB was needed. TRANSFORM II is set to fulfill that need, with initial 12-month outcomes anticipated to shed light on the long-term benefits of avoiding permanent implants in coronary vessels.
Dr. Manish Doshi, Founder & Managing Director of Concept Medical Group, commented: "The completion of patient enrollment in TRANSFORM II is a significant milestone in our mission to bring innovative drug-delivery technologies to the forefront of interventional cardiology. We are proud to scientifically support one of the largest global randomized trials evaluating sirolimus-coated balloon technology. This achievement reflects our commitment to clinical excellence, scientific rigor, and ultimately, better outcomes for patients around the world."
About MagicTouch SCB
The MagicTouch SCB, developed by Concept Medical Inc., utilizes proprietary Nanoluté technology to deliver sub-micron particles of sirolimus encapsulated in a biocompatible carrier, ensuring deep penetration into the vessel wall. The device has received CE Mark approval in Europe alongwith Breakthrough Device Designation & IDE Approval from the U.S. FDA for the treatment of small coronary vessels and in-stent restenosis with ongoing clinical trials.
About Concept Medical Inc.
Concept Medical Inc., headquartered in Tampa, Florida, has a global presence and is dedicated to enhancing patient care through cutting-edge research and development of drug-delivery technologies. Its proprietary platforms are designed to deliver pharmaceutical agents across vascular luminal surfaces with unparalleled precision. Concept Medical is the developer of the MagicTouch family of Sirolimus-Coated Balloons (SCB) – the world's first and most utilized SCB technology – well recognized for its versatility and efficacy in treating coronary and peripheral artery disease. The revolutionary MagicTouch and Abluminus product lines have been used to treat over a million patients globally, setting a new standard for vascular therapy.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
9 hours ago
- Cision Canada
Media Advisory - Simultaneous launch of Canadian space technologies Français
LONGUEUIL, QC, June 21, 2025 /CNW/ - Several technologies funded by the Canadian Space Agency under the Space Technology Development Program will be launched into space by SpaceX. These projects are a testament to Canada's leadership in space innovation. EarthDaily Analytics will use high-precision thermal imagers to monitor plant transpiration. The data collected could help farmers make decisions about irrigation, fertilization and crop rotation. It could also provide precise information about areas at greatest risk of wildfires, in order to protect our communities. INO provided infrared cameras as part of this project. Galaxia will launch its first satellite, MÖBIUS-1, a software-defined satellite designed to carry various types of Earth observation sensors. The MÖBIUS constellation could be used for a variety of applications, such as defence, environmental monitoring, agriculture, infrastructure, maritime operations and transportation. GHGSat will add two satellites to its commercial constellation, bringing the company's total to 13 methane detection satellites and one CO 2 detection satellite. Mission Control will test its onboard artificial intelligence (AI) software and machine learning operations system SpacefarerAI™ in partnership with Spire Global. Their Persistence mission aims to show how AI can analyze satellite images directly in space, thereby eliminating the need to send all data to Earth for processing. Xona Space Systems will test Pulsar, a demonstration satellite designed to validate a new generation of satellite navigation from low Earth orbit. This technology could improve precision and reliability of positioning services, including in urban areas, remote areas and the Arctic. Also contributing to the GHGSat and EarthDaily Analytics satellites are ABB 's business unit in Quebec, supplying sophisticated optical sensors, and Xiphos Systems, providing high-performance onboard processors. These innovations demonstrate the ability of Canadian companies to develop innovative technologies that meet the needs of the space program and have strong commercial potential. Media who wish to speak with a Canadian Space Agency expert or a representative from one of these Canadian companies are asked to contact the Media Relations Office.
Cision Canada
9 hours ago
- Cision Canada
Statement by Prime Minister Carney on National Indigenous Peoples Day Français
OTTAWA, ON, /CNW/ - "In my first months as Prime Minister, I have been grateful for the opportunity to meet with First Nations, Inuit, and Métis, and I recognize there is much more work to do together. "The government will work in full partnership with Indigenous Peoples – advancing shared priorities such as health care, food security, housing, education, economic prosperity, conservation, climate action, and emergency management to build a better future. Indigenous partnership is a critical component of the One Canadian Economy Act, and shared leadership with First Nations, Inuit, and Métis will be pivotal to the success of building major projects in Canada. "We will move forward together on the Truth and Reconciliation Commission's Calls to Action, the National Inquiry into Missing and Murdered Indigenous Women and Girls' Calls for Justice, and the implementation of the United Nations Declaration on the Rights of Indigenous Peoples Act. "Supporting Indigenous communities, advancing self-determination, implementing treaties, and creating generational wealth and prosperity are central to our commitment to advancing reconciliation. Through initiatives like the Indigenous Loan Guarantee Program, we're addressing the historical, systemic, and economic barriers that have prevented Indigenous Peoples from participating in – and benefitting from – economic opportunities, particularly in the natural resource sector. "Today, on National Indigenous Peoples Day, and every day, we honour the enduring histories, cultures, and contributions of First Nations, Inuit, and Métis, and we reaffirm our partnership in reconciliation. Together, we can build a better future, a stronger economy, and a legacy that future generations can inherit and carry forward."
Cision Canada
11 hours ago
- Cision Canada
Statement by Minister Valdez to mark National Indigenous Peoples Day Français
OTTAWA, ON, /CNW/ - The Honourable Rechie Valdez, Minister of Women and Gender Equality and Secretary of State (Small Business and Tourism), made the following statement: "Today, I join communities across the country in celebrating National Indigenous Peoples Day. "This is a time to honour the rich histories, vibrant cultures and enduring contributions of First Nations, Inuit, and Métis. From coast to coast to coast, we celebrate the strength, resilience, and leadership of Indigenous communities. "Today, more than 50,000 small businesses are majority-owned by Indigenous entrepreneurs. Indigenous-led businesses are fuelling economic growth and uplifting communities across the country. "In 2023 alone, Indigenous tourism operators generated an estimated 34,700 jobs and billions of dollars in economic activity. These numbers tell a powerful story of resilience and innovation and highlight the vital role Indigenous businesses play in our tourism economy. "As Minister of Women and Gender Equality, I am committed to supporting Indigenous-led efforts to end gender-based violence. Through the National Action Plan to End Gender-Based Violence and the Federal Pathway to Address Missing and Murdered Indigenous Women, Girls and 2SLGBTQQIA+ Peoples, our government is working in partnership with First Nations, Inuit and Métis communities to develop policies and fund programs to end the national crisis facing Indigenous women, girls and 2SLGBTQQIA+ people. This work is essential to healing, justice and safety for Indigenous women, girls and 2SLGBTQQIA+ people, wherever they live. "Our government is deeply committed to advancing reconciliation and to building lasting partnerships with Indigenous Peoples by supporting entrepreneurs, fostering economic opportunity and building an inclusive economy that leaves no one behind. Stay connected Follow the department on . For easy access to government programs for businesses, download the Canada Business app.
